title: Association of sexual dysfunction with lower urinary tract symptoms of BPH and BPH medical therapies: results from the BPH Registry.
abstract: OBJECTIVE
  The severity of lower urinary tract symptoms (LUTS) has correlated with erectile dysfunction (ED) and ejaculatory dysfunction (EjD) in large-scale epidemiologic studies. ED and EjD are also side effects of some medical therapies for LUTS suggestive of benign prostatic hyperplasia (LUTS/BPH). These relationships were examined in a physician office-based population of men enrolled in the BPH Registry.
  
  
  METHODS
  Enrolled men with LUTS/BPH who completed the International Prostate Symptom Score (IPSS), IPSS bother question, 5-item International Index of Erectile Function, and the 3 ejaculatory function items of the Male Sexual Health Questionnaire-EjD short form at baseline were eligible. The relationship between sexual dysfunction and LUTS/BPH and BPH medical therapies were examined using multivariate analyses.
  
  
  RESULTS
  Of 6924 men enrolled, 5042 (mean age 65 years) completed all 4 baseline assessments. Of 3084 sexually active men, age, total IPSS, IPSS bother score, hypertension, diabetes, and black race/ethnicity were independent predictors of both ED and EjD (all P < .05). For the subset of 1362 men receiving BPH medical therapy, a significant association (P < .0001) was demonstrated for ED and EjD with specific BPH medical therapies. The alpha(1A)-subtype nonsuperselective quinazoline alpha(1)-blockers alfuzosin, doxazosin, and terazosin appeared to be associated with better ejaculatory function than were the alpha(1A)-subtype superselective sulfonamide alpha(1)-blocker tamsulosin, 5alpha-reductase inhibitors, and alpha(1)-blocker plus 5alpha-reductase inhibitor combination therapy.
  
  
  CONCLUSIONS
  These results have provided additional evidence of the link between LUTS/BPH and sexual dysfunction in aging men and support clinical trial results indicating different rates of sexual side effects for BPH medical therapies.
authors.affiliation: New England Research Institutes, Watertown, Massachusetts 02472, USA. rrosen@neriscience.com
authors.forename: Raymond C
authors.initials: RC
authors.lastname: Rosen
authors.forename: John T
authors.initials: JT
authors.lastname: Wei
authors.forename: Stanley E
authors.initials: SE
authors.lastname: Althof
authors.forename: Allen D
authors.initials: AD
authors.lastname: Seftel
authors.forename: Martin
authors.initials: M
authors.lastname: Miner
authors.forename: Michael A
authors.initials: MA
authors.lastname: Perelman
mesh_terms: D000368:Aged; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011470:Prostatic Hyperplasia / Q000150:complications* / Q000628:therapy*; D053448:Prostatism / Q000150:complications*; D012042:Registries; D012735:Sexual Dysfunction, Physiological / Q000209:etiology*